<DOC>
	<DOCNO>NCT02154646</DOCNO>
	<brief_summary>The main purpose study evaluate safety side effect LY2157299 combination gemcitabine Japanese participant pancreatic cancer advance spread another part body .</brief_summary>
	<brief_title>A Study LY2157299 Participants With Pancreatic Cancer That Advanced Has Spread Another Part Body</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Have histological cytological diagnosis adenocarcinoma pancreas locally advance metastatic amenable resection curative intent . These participant may receive prior chemotherapy , radiotherapy , cancerrelated hormone therapy , investigational therapy treatment chemotherapy . Participants previous radical surgery pancreatic cancer eligible progression document . Have measurable disease nonmeasurable disease , define accord Response Evaluation Criteria Solid Tumors ( RECIST ) . Have give write informed consent prior studyspecific procedure . Have adequate organ function . Have performance status less equal 1 Eastern Cooperative Oncology Group ( ECOG ) . Are reliable willing make available duration study willing follow study procedure . Prior radiation therapy treatment cancer allow less 25 % bone marrow , participant must recover acute toxic effect treatment prior study enrollment . Prior radiation whole pelvis allow . Males female reproductive potential : Must agree use medically approve contraceptive precaution study 3 month follow last dose study drug . Are currently enrol , discontinue within last 30 day study enrollment , clinical trial involve investigational product nonapproved use drug device , concurrently enrol type medical research judge scientifically medically compatible study . Have moderate severe cardiac disease : Myocardial infarction within 6 month prior study enrollment , unstable angina pectoris , New York Heart Association ( NYHA ) Class III/IV congestive heart failure , uncontrolled hypertension . Documented major electrocardiogram ( ECG ) abnormalities investigator 's discretion . Major abnormality document echocardiography Doppler . Have significantly elevate brain natriuretic peptide ( BNP ) elevate Troponin I screen local laboratory test . Predisposing condition consistent development aneurysm ascend aorta aortic stress . Have history cardiac aortic surgery . Have know positive test human immunodeficiency virus ( HIV ) , hepatitis B , hepatitis C virus antibody ( HCVAbs ) . Have symptomatic central nervous system ( CNS ) malignancy metastasis . Are unable swallow tablet capsule . Are pregnant breastfeeding . Have serious preexist medical condition follow : Presence history interstitial pneumonitis . Uncontrollable severe diabetes . Presence serious active infection uncontrollable chronic infection . Presence liver cirrhosis ChildPugh Stage B C. Other serious condition judge investigator . Have previous concurrent malignancy except basal squamous cell skin cancer ( nonmelanoma ) and/or preinvasive carcinoma cervix , mucosal gastrointestinal uterine carcinoma , solid tumor treat curatively without evidence recurrence least 3 year prior enrollment . Have endocrine pancreatic tumor ampullary cancer . Have current hematological malignancy . Have previously complete withdrawn study study investigate LY2157299 . Have know allergy LY2157299 gemcitabine ingredient LY2157299 gemcitabine formulation . Are assessed inadequate study investigator .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>